Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma
September 14th 2019Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).
Daratumumab-VTd Regimen Shows Benefit in Newly Diagnosed High-Risk Multiple Myeloma
September 14th 2019Pieter Sonneveld, MD, PhD, discusses the significance of the subgroup analysis of the phase III CASSIOPEIA trial evaluating the regimen of daratumumab, bortezomib, thalidomide, and dexamethasone in patients with high-risk multiple myeloma.